A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 16 Dec 2019
Price : $35 *
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 11 Dec 2019 Planned End Date changed from 30 Nov 2020 to 30 Jan 2021.
- 30 Sep 2019 Planned primary completion date changed from 30 Sep 2019 to 21 Nov 2019.
- 07 Aug 2019 Status changed from recruiting to active, no longer recruiting, according to an Biohaven Pharmaceutical Holding Company media release.